Gyrate atrophy of the choroid and retina is known in association with hyperornithinaemia.' Although a deficiency of ornithine-ketoacid-transaminase (OKT) was found to cause the disorder,'-5 the pathogenic mechanism responsible for the chorioretinal lesion is still obscure, as is a generally accepted management of the disease. To date three major trials for the management of gyrate atrophy have been reported6: (1) pyridoxine or vitamin B6,'8 (2) lowprotein and arginine-restricted diets,9-'2 and (3) creatine. 13
Gyrate atrophy of the choroid and retina is known in association with hyperornithinaemia.' Although a deficiency of ornithine-ketoacid-transaminase (OKT) was found to cause the disorder,'-5 the pathogenic mechanism responsible for the chorioretinal lesion is still obscure, as is a generally accepted management of the disease. To date three major trials for the management of gyrate atrophy have been reported6: (1) pyridoxine or vitamin B6,'8 (2) lowprotein and arginine-restricted diets,9-'2 and (3) creatine. 13 We tried vitamin B6 (pyridoxine) administration in vitamin B6-responsive (case 3) and non-responsive (case 2) patients, and proline supplementation in vitamin B6-non-responsive patients (cases 1, 2, 4, and 5). Biochemical parameters (serum amino acid levels) and visual function tests (visual acuity, visual field, dark adaptation, electroretinogram, and colour sense) were mainly examined to evaluate the trials in a manner similar to that described by others.8 9 1 The slow progression of sharply defined chorioretinal Correspondence to S Hayasaka, MD, Department of Ophthalmology, Tohoku University School of Medicine, Sendai, Miyagi 980, Japan. atrophic lesions is most characteristic in this disorder. We therefore compared the extent of sharply defined lesions before and after our trials.
Material and methods
Ocular manifestations and biochemical abnormalities of the cases presented here have been previously reported in part elsewhere.' '6 The daily doses of proline and/or vitamin B6 were divided into three equal parts, given orally at 7.00 am, 12.00 am, and 5.30 pm.
Blood samples were drawn usually between 6.30 and 8.00 am after 10 hours of fasting. Serum was separated, and the amino acid concentration was estimated with an amino acid analyser (Hitachi 835). Fasting serum amino acids were examined every four or six months, and the mean values are shown in the tables.
The electroretinograms, electro-oculograms, fundus photographs, visual fields (Goldmann perimeter), and dark adaptations (GoldmannWeeker instrument) were recorded with the same equipment and techniques throughout the study, as previously reported.' 146 283 
Discussion
We evaluated trials of vitamin B6 (pyridoxine) and supplementary proline for gyrate atrophy. The biochemical basis for the vitamin B6 trial was as follows. We previously reported on a patient (case 3) who was vitamin B6-responsive and whose serum ornithine level decreased to a maximum of 60% after the vitamin therapy (600 mg/day). 14 The vitamin partially activates the activity of OKT and is expected to halt the progression of the chorioretinal atrophy. Vitamin B6 was tried in a B6-non-responsive patient (case 3) as well.
The biochemical basis for the proline supplementation was as follows. We found (1) a disturbance of de-novo formation of proline in affected patients.'7 Serum proline increased after oral loading of ornithine in normal controls, whereas the proline in the patients did not increase. (2) The .OKT activity was high in the retina and choroid, particularly in the retinal pigment epithelium, in bovine and human eyes. Ix19 The retinal pigment epithelium and neuroretina lack proline oxidase activity2"; A'-pyrroline-5-carboxylate dehydrogenase activity is low in the retina20; and A'-pyrroline-5-carboxylate reductase activity is high in the retina and choroid.2" Ornithine in the retina may be converted into proline by the cooperative action of OKT and A'-pyrroline-5-carboxylate reductase.2' Furthermore, the importance of ornithine as a precursor for proline in mammalian cells has been proposed. by others.2' The intraocularly injected radioisotope-labelled ornithine The above data strongly suggest that a deficiency of proline in the retina and choroid may produce atrophies in affected patients despite normal serum proline levels. Supplementary proline, therefore, is supposed to diffuse into the tissues and halt the progression of the atrophy.
In case 1 the visual acuity did improve after supplementary proline, and the refractive error lessened. Although myopic changes with age are usually noted in this disorder, the refractive error lessened in case 1. Yellowish white spots in the peripheral fundus seemed to increase only minimally, and the deterioration of ERG response was only slight. At age 9 years the chorioretinal lesions were much smaller and fewer than those in patients of the same or younger ages who received no proline supplementation."4 2426
The serum proline level in case 2 did not increase despite the vitamin B6 and supplementary proline, and the hyperornithinaemia was not improved. A marked progression of chorioretinal atrophy and vitreous haemorrhage was observed.
In case 3 the daily dose of 600 mg vitamin B6 induced the maximal reduction of the serum ornithine level: the higher dose over 600 mg vitamin B6 could not reduce the ornithine level to normal range. Despite a reduced ornithine level after vitamin B6 therapy areas of chorioretinal atrophy enlarged. His poor visual acuity in the light eye was thought to be amblyopia.
In case 4 the posterior subcapsular cataract progressed slightly despite the supplementary proline. Regions of chorioretinal atrophy were probably unchanged. In case 5 visual functions and chorioretinal atrophic areas did not change during the trial of supplementary proline.
Vitreous haemorrhage can occur in association with the disorder.'6 Therefore it is unlikely that the haemorrhage in case 2 is a complication of supplementary proline. No obvious complication associated with the supplementary proline was observed, suggesting that hyperprolinaemia is probably harmless.27 Giordano and associates28 proposed the efficacy of lysine supplementation in gyrate atrophy, but visual improvement was not described. Serum lysine levels in all our cases were below normal range and did not change during proline supplementation. Although the natural progression of the disease is not well known, acuities in phakic eyes tend to decrease from 20/30 to 20/200 in 10 years or less, and constriction of visual fields with age is marked. 29 Takki and Milton29 reported no clinical correlation between the extent of chorioretinal atrophy and age except in patients younger than 13-15 years. Therefore the extent and progression of the atrophy in our cases 1 and 2 are suitable for evaluating the trials. After proline supplementation the chorioretinal lesions progressed only minimally in case 1. Despite the supplementation of the vitamin and proline, the serum proline level did not increase and the chorioretinal atrophy progressed in case 2. We conclude (1) that vitamin B6 does not halt the progression of chorioretinal atrophy in these patients, even if the serum ornithine level is reduced after vitamin supplementation, and (2) that the supplementary proline may minimise the progression of chorioretinal atrophy. 
